Home drug reform Page 10

Keyword: drug reform

166 results found
Sanofi survey finds 85% of plan members used drug plans last year

The majority (85 per cent) of Canadian plan members used their drug plan at least once in the past year, according to the 2018 Sanofi Canada health-care survey. Among plan members who submitted drug claims, the average number per year was 9.4. That figure rose to 14.5 claims for both employees in poor health and those […]

  • By: Staff
  • June 13, 2018 September 13, 2019
  • 11:02
Editorial: Of drugs and dentists: The best-laid plans or a political ploy?

It’s not often that the issues relevant to benefits plans emerge as an area of focus in the political realm. But with votes up for grabs and politicians eager to find any way to harness them, it appears issues of drugs and dental care are moving up the political agenda. In the federal arena, the […]

Federal patent changes to add new costs to drug plans, report predicts

New federal legislation around pharmaceutical patents will impose significant costs on public and private drug plans, the parliamentary budget officer is predicting. The legislation would have cost drug plans and consumers an extra $392 million in 2015 had it been in place that year, the report, released in late April, estimates. Of that, $214 million […]

Have your say: Did Commons committee get it right on pharmacare?

In last week’s report on pharmacare, the House of Commons’ standing committee on health recommended a significant departure from the current mix of private drug coverage supplemented by public programs. While the report referenced various provincial drug programs that supplement private benefits plans or cover those without their own insurance — including those offered by Quebec, […]

Commons committee recommends national pharmacare program

The House of Commons’ standing committee on health is recommending the creation of a universal, single public payer prescription drug coverage program for all Canadians. “The committee believes that the best approach for the creation of such a program is through the expansion of the Canada Health Act to include prescription drugs dispensed outside of hospitals as an insured service,” […]

  • By: Staff
  • April 19, 2018 September 13, 2019
  • 10:15
OHIP+ for seniors a ‘significant win’ for employers with retiree benefits plans

Ontario’s move to expand its youth pharmacare program to seniors in 2019 could be a significant win for plan sponsors offering retiree benefits. “A company would see significant balance-sheet reduction and lower accounting expense, as well as lower cash costs,” says Nabil Merali, senior vice-president and Ontario market leader for health and benefits at Aon Hewitt. […]

Ontario unveils new drug, dental coverage for people without workplace benefits

While Wednesday’s provincial budget in Ontario offered details on the inclusion of seniors in the government’s pharmacare program, Ontarians over age 65 aren’t the only cohort set to benefit from expanded drug coverage. Through the introduction of the Ontario drug and dental program, all Ontarians will be eligible for some coverage in those areas if they aren’t already […]

Ontario Trillium program sees rise in young users, spend on high-cost drugs

The number of Ontarians using the Trillium drug program increased threefold between the beginning of 2000 and the end of 2016, according to a new study published in the Canadian Medical Association Journal. Between 2000 and 2015, the number of overall Trillium recipients increased 176,299 from 55,571. During the same time frame, the proportion of plan beneficiaries […]

  • By: Staff
  • March 27, 2018 September 13, 2019
  • 16:30
Lower generic prices not a cure for drug cost pressures

The announcement in late January that 70 of the most commonly prescribed drugs will see their prices fall by as much as 40 per cent on April 1 was certainly welcome news for plan sponsors. The deal, reached by the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association, will bring the cost of some generic products down […]

  • March 26, 2018 September 13, 2019
  • 16:14
How changing public coverage could affect the pharmaceuticals industry

The hepatitis C hump is over. Since 2014, Health Canada has approved several promising medications for the disease. While the direct-acting antivirals offer cure rates of more than 90 per cent, they cost tens of thousands of dollars, and benefits plans felt the pinch. But now, “after an initial spike in treatment requests, claims have […]